Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Granulocyte colony-stimulating factor Stories

2009-09-17 10:00:00

BOULDER, Colo., Sept. 17 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded two Phase I Small Business Innovation Research (SBIR) grants totaling $1.2 million from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH). The grants will be used to perform additional preclinical toxicology and pharmacology studies of the company's proprietary long-acting G-CSF and GM-CSF analogs. Receipt of the entire...

2009-07-02 10:52:50

U.S. scientists say a human growth factor used to stimulate blood stem cells to proliferate in bone marrow can also reverse memory impairment in mice. Researchers at the University of South Florida and Haley Hospital, both in Tampa, Fla., genetically altered mice to develop Alzheimer's disease. The scientists found the growth factor -- granulocyte-colony stimulating factor -- significantly reduced levels of the brain-clogging protein beta amyloid found in abundance in the brains of the...

708c3a5e7be916d109ef8ac3d6b7f2e7
2009-07-01 16:00:00

The new study shows GCSF impacts both bone marrow and brain to improve cognition A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A. Haley Hospital found. The granulocyte-colony stimulating factor (GCSF) significantly reduced levels of the brain-clogging protein beta amyloid deposited in excess in the...

2009-04-02 12:33:30

A new study in mice shows that a dual therapy can lead to generation of new blood vessels and improved cardiac function following a heart attack. The research, published by Cell Press in the April 3rd issue of the journal Cell Stem Cell, provides an explanation for the ineffectiveness of current stem-cell-mobilizing therapies and may drive design of future regenerative therapies for the heart.Stem-cell-based therapies are an attractive option for the treatment of heart damage after a heart...

838c9e165de184dc2088e417a30f467b1
2009-01-16 13:30:00

Researchers have reported findings that suggest a treatment commonly used to help premature babies fight infection is ineffective.Researchers studied 280 babies born at 31 weeks or under to form their surprising conclusion reported in The Lancet.Doctors have used granulocyte-macrophage colony stimulating factor (GM-CSF) in order to help prematurely born infants naturally boost their immune systems by increasing white blood cell growth to prevent blood poisoning. GM-CSF is effective in...

2008-12-19 16:38:40

The U.S. Food and Drug Administration has approved the drug Mozobil for treatment of adults with multiple myeloma or non-Hodgkin's lymphoma. The drug, manufactured by Genzyme Corp., Cambridge, Mass., has been found to help increase the number of blood stem cells for bone marrow transplantation in patients with certain blood cancers, the agency said Thursday in a release. Mozobil is intended to be used in combination with the growth factor granulocyte-colony stimulating factor. Collecting the...

2008-10-27 09:00:41

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a series of studies demonstrating Protectan CBLB612's ability to substantially reduce myelosuppression (the most common rate limiting adverse effect of chemotherapy) caused by a widely used chemotherapeutic drug, cyclophosphamide (Cytoxan, Neosar, CTX). Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, stated: "Our previous studies established Protectan CBLB612's activity as a potent...

2008-10-27 06:00:23

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured. The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating...

2008-07-28 12:01:07

Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics. The International Union of Basic and Clinical Pharmacology is hosting this Annual Scientific Meeting in Quebec City, Canada from July 27-August 1, 2008. The abstract is entitled "GlycoPEGylated G-CSF XM22...

2008-07-10 09:01:29

RICHMOND, Va., July 10, 2008 /PRNewswire-FirstCall/ -- Insmed Inc. , a developer of follow-on biologics and biopharmaceuticals for unmet medical needs, today announced that it has demonstrated the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF), compared to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of approximately $1 billion. Human bioequivalence studies utilize...